Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes
P Dalén, ML Dahl, M Eichelbaum… - Pharmacogenetics …, 1999 - journals.lww.com
Debrisoquine is a major prototypic in-vivo probe used to assess polymorphic CYP2D6
activity in humans, based on the 0–8 h urinary excretion of unchanged drug and its 4 …
activity in humans, based on the 0–8 h urinary excretion of unchanged drug and its 4 …
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene
F Broly, UA Meyer - Pharmacogenetics and Genomics, 1993 - journals.lww.com
A mutant allele of the CYP2D6 gene (CYP2D6* C) characterized by a 3-base-pair deletion
in exon 5 (mutation D6-C) and carried by a Xba I 29 kb restriction fragment (haplotype 29-C) …
in exon 5 (mutation D6-C) and carried by a Xba I 29 kb restriction fragment (haplotype 29-C) …
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
ML Bernal, B Sinues, I Johansson… - Pharmacogenetics …, 1999 - journals.lww.com
The debrisoquine/sparteine hydroxylation polymorphism is clinically important as the
involved enzyme CYP2D6 catalyses the metabolism of many important drugs such as …
involved enzyme CYP2D6 catalyses the metabolism of many important drugs such as …
CYP2D6 -1584C>G Promoter Polymorphism and Debrisoquine Ultrarapid Hydroxylation in Healthy Volunteers
Background & aim: The CYP2D6-1584C> G polymorphism (rs1080985) has been identified
as a major factor for CYP2D6 expression and function, with the mutant-1584G promoter type …
as a major factor for CYP2D6 expression and function, with the mutant-1584G promoter type …
PCR-based genotyping for duplicated and deleted CYP2D6 genes
I Johansson, E Lundqvist, ML Dahl… - Pharmacogenetics …, 1996 - journals.lww.com
The debrisoquine hydroxylase (CYP2D6), which metabolizes more than 30 different drugs,
is highly polymorphic. In subjects having either very low or very high enzyme activity, drug …
is highly polymorphic. In subjects having either very low or very high enzyme activity, drug …
Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous …
WE Evans, MV Relling - Pharmacogenetics and Genomics, 1991 - journals.lww.com
Abstract Debrisoquine-hydroxylase (P450 2D6)‡ phenotype was determined in 116
individuals using dextromethorphan as the substrate probe. Polymerase chain reaction and …
individuals using dextromethorphan as the substrate probe. Polymerase chain reaction and …
Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population Reduced enzyme activity and evaluation of metabolic …
C Masimirembwa, J Hasler, L Bertilssons… - European journal of …, 1996 - Springer
Abstract Objective: Debrisoquine hydroxylase (CYP2D6) is responsible for the oxidative
metabolism of many clinically used drugs. Since this enzyme has been poorly studied in the …
metabolism of many clinically used drugs. Since this enzyme has been poorly studied in the …
Interpretation of a simple PCR analysis of the CYP2D6 (A) and CYP2D6 (B) null alleles associated with the debrisoquine/sparteine genetic polymorphism
AM Douglas, BA Atchison, AA Somogyi… - Pharmacogenetics …, 1994 - journals.lww.com
The debrisoquine-4-hydroxylase polymorphism is a genetic variation in oxidative drug
metabolism characterized by two phenotypes, the extensive metabolizer (EM) and poor …
metabolism characterized by two phenotypes, the extensive metabolizer (EM) and poor …
Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes
AK Daly, M Armstrong, SC Monkman… - Pharmacogenetics …, 1991 - journals.lww.com
A randomly selected population of 73 volunteers, together with 22 previously established
poor metabolisers of debrisoquine, were phenotyped for their ability to 4-hydroxylate …
poor metabolisers of debrisoquine, were phenotyped for their ability to 4-hydroxylate …